Richard Wells
Overview
Explore the profile of Richard Wells including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
609
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stapleton P, Fuller A, Singh-Rai R, Wells R, Bak E
J Robot Surg
. 2024 Nov;
19(1):8.
PMID: 39579304
BPH is a common urological pathology that affects 2480 per 100,000 men worldwide. With a rising population and increased age expectancy, the prevalence of benign prostatic hyperplasia (BPH) is increasing...
2.
3.
Schrezenmeier H, Kulasekararaj A, Mitchell L, Peffault de Latour R, Devos T, Okamoto S, et al.
Ann Hematol
. 2023 Oct;
103(1):5-15.
PMID: 37804344
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by uncontrolled terminal complement activation leading to intravascular hemolysis (IVH), thrombosis, and impairments in quality of life (QoL). The aim of this study was...
4.
Magarbeh L, Gorbovskaya I, Wells R, Jhirad R, Le Foll B, Muller D
J Pers Med
. 2023 Jun;
13(6).
PMID: 37373907
There has been a worldwide substantial increase in accidental opioid-overdose deaths. The aim of this review, along with preliminary results from our pilot study, is to highlight the use of...
5.
Koot E, Wu C, Ruza I, Hilario E, Storey R, Wells R, et al.
Evol Appl
. 2021 Dec;
14(12):2848-2863.
PMID: 34950233
The assessment of the genetic structuring of biodiversity is crucial for management and conservation. This is particularly critical for widely distributed and highly mobile deep-water teleosts, such as hoki ()....
6.
Kulasekararaj A, Hill A, Langemeijer S, Wells R, Gonzalez Fernandez F, Gaya A, et al.
Eur J Haematol
. 2020 Dec;
106(3):389-397.
PMID: 33301613
Ravulizumab every 8 weeks showed non-inferiority to eculizumab every 2 weeks in a 26-week, phase 3, randomized controlled trial in adults with paroxysmal nocturnal hemoglobinuria (PNH) who were clinically stable...
7.
Schrezenmeier H, Kulasekararaj A, Mitchell L, Sicre de Fontbrune F, Devos T, Okamoto S, et al.
Ther Adv Hematol
. 2020 Nov;
11:2040620720966137.
PMID: 33178408
Background: Ravulizumab, the only long-acting complement C5 inhibitor for adults with paroxysmal nocturnal hemoglobinuria (PNH), demonstrated non-inferiority to eculizumab after 26 weeks of treatment in complement inhibitor-naïve patients during a...
8.
Peipert J, Kulasekararaj A, Gaya A, Langemeijer S, Yount S, Gonzalez-Fernandez F, et al.
PLoS One
. 2020 Sep;
15(9):e0237497.
PMID: 32886668
Background: Eculizumab has transformed management of paroxysmal nocturnal hemoglobinuria (PNH) since its approval. However, its biweekly dosing regimen remains a high treatment burden. Ravulizumab administered every 8 weeks demonstrated noninferiority...
9.
Kaiser K, Yount S, Martens C, Webster K, Shaunfield S, Sparling A, et al.
Patient Prefer Adherence
. 2020 Apr;
14:705-715.
PMID: 32308375
Purpose: To develop a patient preference questionnaire (PPQ) assessing eculizumab and ravulizumab treatment for paroxysmal nocturnal hemoglobinuria (PNH). Patients And Methods: The development of the PNH-PPQ was consistent with Food...
10.
Garcia-Manero G, Griffiths E, Steensma D, Roboz G, Wells R, McCloskey J, et al.
Blood
. 2020 Apr;
136(6):674-683.
PMID: 32285126
This phase 2 study was designed to compare systemic decitabine exposure, demethylation activity, and safety in the first 2 cycles with cedazuridine 100 mg/decitabine 35 mg vs standard decitabine 20...